VIVAGLOBIN Side Effects

7040034-4 | Blood Pressure Decreased, Cerebral Infarction, Cerebrovascular Accident, Dehydration, Headache, Migraine, Nausea
on Sep 09, 2010 Female patient from UNITED STATES , weighting 159.0 lb, was diagnosed with immunodeficiency common variable and was treated with Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure decreased, cerebral infarction, cerebrovascular accident, dehydration, headache (What is headache?), migraine (What is migraine?), nausea (What is nausea?). Vivaglobin dosage: 56 Ml, 56 Ml Weekly In 4 Sites Over 1 Hour Subcuataneous. During the same period patient was treated with ZANTAC (View Zantac Review and Zantac Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), FLAXSEED (LINUM USITATISSIMUM SEED OIL) (View Flaxseed (linum Usitatissimum Seed Oil) Review and Flaxseed (linum Usitatissimum Seed Oil) Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ), ZETIA (View Zetia Review and Zetia Label ), SYNTHROID (View Synthroid Review and Synthroid Label ). Patient was hospitalized.

7039437-3 | Blood Pressure Decreased, Cerebral Infarction, Cerebrovascular Accident, Dehydration, Infusion Related Reaction, Migraine
Patient was taking Vivaglobin (View Usage). Patient had the following side effects: blood pressure decreased, cerebral infarction, cerebrovascular accident, dehydration, infusion related reaction, migraine (What is migraine?) on Sep 14, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 159.0 lb, was diagnosed with immunodeficiency common variable and. Vivaglobin dosage: (56 Ml, 56 Ml Weekly In 4 Sites Over 1 Hour Subcutaneous). During the same period patient was treated with ZANTAC (View Zantac Review and Zantac Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), FLAXSEED (LINUM USIATISSIMUM SEED OIL) (View Flaxseed (linum Usiatissimum Seed Oil) Review and Flaxseed (linum Usiatissimum Seed Oil) Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ), ZETIA (View Zetia Review and Zetia Label ), SYNTHROID (View Synthroid Review and Synthroid Label ). Patient was hospitalized.

7028549-6 | Blood Pressure Decreased, Cerebral Infarction, Cerebrovascular Accident, Dehydration, Migraine, Nausea
Adverse event was reported on Aug 17, 2010 by a Female patient taking Vivaglobin (View Usage) (Dosage: (56 Ml, 56 Ml Weekly In 4 Sites Over 1 Hour Subcutaneous)) was diagnosed with immunodeficiency common variable and. Location: UNITED STATES , weighting 159.0 lb, After Vivaglobin was administered, patient had the following side effects: blood pressure decreased, cerebral infarction, cerebrovascular accident, dehydration, migraine (What is migraine?), nausea (What is nausea?). During the same period patient was treated with ZANTAC (View Zantac Review and Zantac Label ), BABY ASPIRIN (ACETYLSALIC ACID) (View Baby Aspirin (acetylsalic Acid) Review and Baby Aspirin (acetylsalic Acid) Label ), FLAXSEED (LINUM USITATISSIMUM SEED OIL) (View Flaxseed (linum Usitatissimum Seed Oil) Review and Flaxseed (linum Usitatissimum Seed Oil) Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ), ZETIA (View Zetia Review and Zetia Label ), SYNTHROID (View Synthroid Review and Synthroid Label ). Patient was hospitalized.

6942013-1 | Blood Pressure Decreased, Cerebrovascular Accident, Dehydration, Dysarthria, Headache, Migraine, Nausea
on Aug 10, 2010 Female patient from UNITED STATES , 73 years of age, was diagnosed with immunodeficiency common variable and was treated with Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: blood pressure decreased, cerebrovascular accident, dehydration, dysarthria, headache (What is headache?), migraine (What is migraine?), nausea (What is nausea?). Vivaglobin dosage: (56 Ml, 56 Ml Weekly In 4 Sites Over 1 Hours Subcutaneous). During the same period patient was treated with ZANTAC 150 (View Zantac 150 Review and Zantac 150 Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), FLAXSEED (LINUM USITATISSIMUM SEED OIL) (View Flaxseed (linum Usitatissimum Seed Oil) Review and Flaxseed (linum Usitatissimum Seed Oil) Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ), ZETIA (View Zetia Review and Zetia Label ), SYNTHROID (View Synthroid Review and Synthroid Label ). Patient was hospitalized.


6863200-7 | Emotional Disorder, Infusion Site Erythema, Infusion Site Pain, Infusion Site Pruritus, Infusion Site Swelling, Puncture Site Pain, Stress, Weight Decreased
on Jun 29, 2010 Female patient from UNITED STATES , weighting 175.0 lb, was diagnosed with blood immunoglobulin g decreased and was treated with Vivaglobin (View Usage). Patient had the following side effects: emotional disorder, infusion site erythema, infusion site pain, infusion site pruritus, infusion site swelling, puncture site pain, stress (What is stress?), weight decreased. Vivaglobin dosage: Blood 3 Sites Over 2 Hours Subcutaneous). Patient was hospitalized.

6832125-5 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Haemochromatosis, Hepatitis B Antigen Positive, Infusion Site Erythema, Infusion Site Pruritus, Infusion Site Reaction, Infusion Site Swelling, Infusion Site Urticaria
Patient was taking Vivaglobin (View Usage). After Vivaglobin was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, haemochromatosis, hepatitis b antigen positive, infusion site erythema, infusion site pruritus, infusion site reaction, infusion site swelling, infusion site urticaria on Jun 10, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 122.0 lb, was diagnosed with blood immunoglobulin g decreased and. Vivaglobin dosage: See Image. During the same period patient was treated with ZANTAC 150 (View Zantac 150 Review and Zantac 150 Label ), DIFLUCAN (View Diflucan Review and Diflucan Label ), NYSTATIN (View Nystatin Review and Nystatin Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ).

6766243-7 | Anti-hbc Igg Antibody Positive, Anti-hbs Antibody Positive, False Positive Laboratory Result, Hepatitis B Surface Antigen Positive
Adverse event was reported on May 17, 2010 by a Male patient taking Vivaglobin (View Usage) (Dosage: (9.6 G, 9.6g Weekly (16% Concentration) Subcutaneous), (subcutaneous)) was diagnosed with immunodeficiency common variable and. Location: UNITED STATES , weighting 202.8 lb, Patient experienced the following unwanted or unexpected effects: anti-hbc igg antibody positive, anti-hbs antibody positive, false positive laboratory result, hepatitis b surface antigen positive. During the same period patient was treated with MESALAMINE (View Mesalamine Review and Mesalamine Label ).

6766226-7 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Hepatitis B E Antigen Positive, Infusion Site Swelling, Infusion Site Urticaria, Infusion Site Warmth, Serum Ferritin Increased, White Blood Cell Count Decreased
on May 20, 2010 Female patient from UNITED STATES , weighting 122.0 lb, was diagnosed with blood immunoglobulin g decreased and was treated with Vivaglobin (View Usage). Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, hepatitis b e antigen positive, infusion site swelling, infusion site urticaria, infusion site warmth, serum ferritin increased, white blood cell count decreased. Vivaglobin dosage: (16 Ml, 16 Ml Weekly In 2 Sites Subcutaneous).

6762379-5 | False Positive Laboratory Result, Hepatitis B Surface Antigen Positive
on May 07, 2010 Male patient from UNITED STATES , weighting 202.8 lb, was diagnosed with immunodeficiency common variable and was treated with Vivaglobin (View Usage). After Vivaglobin was administered, patient had the following side effects: false positive laboratory result, hepatitis b surface antigen positive. Vivaglobin dosage: See Image. During the same period patient was treated with MESALAMINE (View Mesalamine Review and Mesalamine Label ).

6761841-9 | False Positive Laboratory Result, Hepatitis B Surface Antigen Positive, Transmission Of An Infectious Agent Via A Medicinal Product
Patient was taking Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: false positive laboratory result, hepatitis b surface antigen positive, transmission of an infectious agent via a medicinal product on Apr 28, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 202.8 lb, was diagnosed with immunodeficiency common variable and. Vivaglobin dosage: See Image, Subcutaneous. During the same period patient was treated with MESALAMINE (View Mesalamine Review and Mesalamine Label ).

6761835-3 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Hepatitis B E Antigen Positive, Infusion Site Erythema, Infusion Site Pruritus, Infusion Site Reaction, Infusion Site Swelling, Infusion Site Warmth, Serum Ferritin Increased
Adverse event was reported on Apr 22, 2010 by a Female patient taking Vivaglobin (View Usage) (Dosage: See Image, Subcutaneous) was diagnosed with blood immunoglobulin g decreased and. Location: UNITED STATES , weighting 122.0 lb, Patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, hepatitis b e antigen positive, infusion site erythema, infusion site pruritus, infusion site reaction, infusion site swelling, infusion site warmth, serum ferritin increased.

6761694-9 | Cerebrovascular Accident, Pulmonary Embolism
on Apr 28, 2010 Male patient from GERMANY , 52 years of age, was diagnosed with axonal neuropathy and was treated with Vivaglobin (View Usage). After Vivaglobin was administered, patient had the following side effects: cerebrovascular accident, pulmonary embolism (What is pulmonary embolism?). Vivaglobin dosage: Subcutaneous. During the same period patient was treated with GAMUNEX (Intravenous) (View Gamunex Review and Gamunex Label ).

6681965-4 | Antibody Test Positive, False Positive Laboratory Result, Hepatitis B Surface Antigen Positive
on Apr 01, 2010 Male patient from UNITED STATES , weighting 202.8 lb, was diagnosed with immunodeficiency common variable and was treated with Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: antibody test positive, false positive laboratory result, hepatitis b surface antigen positive. Vivaglobin dosage: (9.6 G, 9.6 G Weekly (16% Concentration) Subcutaneous), (subcutaneous). During the same period patient was treated with MESALAMINE (View Mesalamine Review and Mesalamine Label ).

6653872-4 | Arthralgia, Brain Oedema, Chills, Erythema, Localised Oedema, Lymphadenopathy, Speech Disorder Developmental, Visual Impairment
Patient was taking Vivaglobin (View Usage). Patient had the following side effects: arthralgia, brain oedema, chills, erythema, localised oedema, lymphadenopathy, speech disorder developmental, visual impairment on Mar 15, 2010 from BELGIUM Additional patient health information: Female patient , 39 years of age, was diagnosed with hypogammaglobulinaemia, immunodeficiency and. Vivaglobin dosage: 90 Ml, Infusion Rate: 20 Ml/h; Concentration Of Solution: 160 Mg/ml Subcutaneous. During the same period patient was treated with BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), FLUDROCORTISONE ACETATE (View Fludrocortisone Acetate Review and Fludrocortisone Acetate Label ), NASONEX (View Nasonex Review and Nasonex Label ), LYSOMUCIL (ACETYLCYSTEINE) (View Lysomucil (acetylcysteine) Review and Lysomucil (acetylcysteine) Label ), DESORELLE (DESORELLE) (View Desorelle (desorelle) Review and Desorelle (desorelle) Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), ESTIVAN (EBASTINE) (View Estivan (ebastine) Review and Estivan (ebastine) Label ).

6649962-2 | Liquid Product Physical Issue, Product Colour Issue
Adverse event was reported on Mar 24, 2010 by a Female patient taking Vivaglobin (View Usage) (Dosage: 9.6gm Weekly Sq) was diagnosed with immunodeficiency common variable and. Location: UNITED STATES , 66 years of age, weighting 142.0 lb, After Vivaglobin was administered, patient had the following side effects: liquid product physical issue, product colour issue.

6647712-7 | Angioedema, Arthralgia, Gait Disturbance
on Mar 23, 2010 Female patient from UNITED STATES , 66 years of age, weighting 191.0 lb, was diagnosed with immunodeficiency common variable and was treated with Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: angioedema, arthralgia, gait disturbance. Vivaglobin dosage: 8 Grams Weekly Sq Infusion.

6644764-5 | Epistaxis, Haemoglobin Decreased, Idiopathic Thrombocytopenic Purpura, Injury, Petechiae, Telangiectasia
on Feb 28, 2010 Male patient from UNITED STATES , child 7 years of age, was diagnosed with hypogammaglobulinaemia and was treated with Vivaglobin (View Usage). Patient had the following side effects: epistaxis, haemoglobin decreased, idiopathic thrombocytopenic purpura, injury, petechiae, telangiectasia. Vivaglobin dosage: (weekly 100 Mg/kg Subcutaneous) ; (100 Mg/kg Every 2 Weeks Subcutaneous). Patient was hospitalized.

6623521-X | Convulsion
Patient was taking Vivaglobin (View Usage). After Vivaglobin was administered, patient had the following side effects: convulsion on Feb 18, 2010 from UNITED STATES Additional patient health information: Male patient , weighting 230.2 lb, was diagnosed with immunodeficiency common variable and. Vivaglobin dosage: (4.8 G, 4.8 G (0.16g/ml) Over 1 Hour Subcutaneous. During the same period patient was treated with COUMADIN (View Coumadin Review and Coumadin Label ), CYMBALTA (View Cymbalta Review and Cymbalta Label ), MOBIC (View Mobic Review and Mobic Label ), TOPROL XL (View Toprol-xl Review and Toprol-xl Label ), FLOMAX (MORNIFLUMATE) (View Flomax (morniflumate) Review and Flomax (morniflumate) Label ), LUNESTA (View Lunesta Review and Lunesta Label ). Patient was hospitalized.

6607607-1 | Renal Failure Acute
Adverse event was reported on Jan 27, 2010 by a Female patient taking Vivaglobin (View Usage) (Dosage: 49 Ml Weekly In 3 Sites Over 2-4 Hours, Subcutaneous 46 Ml, 46 Ml Weekly, Subcutaneous) was diagnosed with hypogammaglobulinaemia and. Location: UNITED STATES , weighting 235.0 lb, Patient experienced the following unwanted or unexpected effects: renal failure acute. During the same period patient was treated with LYRICA (View Lyrica Review and Lyrica Label ), VITAMIN D (View Vitamin D Review and Vitamin D Label ), YAZ (DROSPERINONE + ETHINYL ESTRADIOL) (ORAL CONTRACEPTIVE NOS) (View Yaz (drosperinone + Ethinyl Estradiol) (oral Contraceptive Nos) Review and Yaz (drosperinone + Ethinyl Estradiol) (oral Contraceptive Nos) Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), DIPHENHYDRAMINE HCL (View Diphenhydramine Hcl Review and Diphenhydramine Hcl Label ), ESTRAETST H.S. (ESTRATEST HS) (View Estraetst H.s. (estratest Hs) Review and Estraetst H.s. (estratest Hs) Label ). Patient was hospitalized.

6607490-4 | Arthralgia, Brain Oedema, Chills, Dizziness, Erythema, Localised Oedema, Lymphadenopathy, Speech Disorder Developmental, Visual Impairment
on Jan 28, 2010 Female patient from BELGIUM , 39 years of age, was diagnosed with hypogammaglobulinaemia, immunodeficiency and was treated with Vivaglobin (View Usage). Patient had the following side effects: arthralgia, brain oedema, chills, dizziness (What is dizziness?), erythema, localised oedema, lymphadenopathy, speech disorder developmental, visual impairment. Vivaglobin dosage: 90 Ml, Infusion Rate: 20 Ml/h; Concentration Of Solution: 160 Mg/ml Subcutaneous. During the same period patient was treated with BISOPROLOL FUMARATE (View Bisoprolol Fumarate Review and Bisoprolol Fumarate Label ), FLUDROCORTISONE ACETATE (View Fludrocortisone Acetate Review and Fludrocortisone Acetate Label ), NASONEX (View Nasonex Review and Nasonex Label ), LYSOMUCIL (ACETYLCYSTEINE) (View Lysomucil (acetylcysteine) Review and Lysomucil (acetylcysteine) Label ), DESORELLE (DESORELLE) (View Desorelle (desorelle) Review and Desorelle (desorelle) Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), ESTIVAN (EBASTINE) (View Estivan (ebastine) Review and Estivan (ebastine) Label ).

6607402-3 | Cerebrovascular Accident, Pulmonary Embolism
on Feb 02, 2010 Male patient from GERMANY , 52 years of age, was treated with Vivaglobin (View Usage). After Vivaglobin was administered, patient had the following side effects: cerebrovascular accident, pulmonary embolism (What is pulmonary embolism?). Vivaglobin dosage: .

6557168-0 | Dizziness, Infusion Site Erythema, Infusion Site Pain, Infusion Site Swelling, Nausea
Patient was taking Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: dizziness (What is dizziness?), infusion site erythema, infusion site pain, infusion site swelling, nausea (What is nausea?) on Jan 27, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 150.4 lb, . Vivaglobin dosage: 49 Ml Once.

6532565-8 | Infusion Site Mass, Infusion Site Pain, Infusion Site Swelling, Infusion Site Urticaria, Kidney Infection, Micturition Urgency
Adverse event was reported on Dec 11, 2009 by a Female patient taking Vivaglobin (View Usage) (Dosage: (50 Ml, 50 Ml Weekly Subcutaneous)) was diagnosed with hypogammaglobulinaemia and. Location: UNITED STATES , weighting 125.0 lb, Patient had the following side effects: infusion site mass, infusion site pain, infusion site swelling, infusion site urticaria, kidney infection, micturition urgency.

6491609-2 | Axillary Vein Thrombosis, Chills, Confusional State, Dental Caries, Lemierre Syndrome, Local Swelling, Mental Status Changes, Nausea, Neck Pain
on Nov 18, 2009 Female patient from UNITED STATES , weighting 115.0 lb, was treated with Vivaglobin (View Usage). After Vivaglobin was administered, patient had the following side effects: axillary vein thrombosis, chills, confusional state, dental caries, lemierre syndrome, local swelling, mental status changes, nausea (What is nausea?), neck pain. Vivaglobin dosage: (50 Ml, 50 Ml Weekly Subcutaneous). During the same period patient was treated with ADVAIR HFA (View Advair Hfa Review and Advair Hfa Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ), FLONASE (View Flonase Review and Flonase Label ), BUSPAR (View Buspar Review and Buspar Label ), LEXAPRO (View Lexapro Review and Lexapro Label ), ASPIRIN (ACETAMINOPHEN ACID) (View Aspirin (acetaminophen Acid) Review and Aspirin (acetaminophen Acid) Label ). Patient was hospitalized.

6449262-X | Headache, Infusion Site Swelling, Nausea, Oedema Peripheral
on Aug 27, 2008 Female patient from UNITED STATES , 50 years of age, weighting 160.0 lb, was diagnosed with blood immunoglobulin g decreased, infection (What is infection?) and was treated with Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: headache (What is headache?), infusion site swelling, nausea (What is nausea?), oedema peripheral. Vivaglobin dosage: 30 Ml Q1w Sc, Sc, Sc. During the same period patient was treated with DIGOXIN (View Digoxin Review and Digoxin Label ), POTASSIUM CHLORIDE (View Potassium Chloride Review and Potassium Chloride Label ).

6449259-X | Abdominal Distension, Chest Pain, Gait Disturbance, Infusion Site Erythema, Infusion Site Pain, Infusion Site Swelling, Infusion Site Warmth, Micturition Urgency
Patient was taking Vivaglobin (View Usage). Patient had the following side effects: abdominal distension, chest pain (What is chest pain?), gait disturbance, infusion site erythema, infusion site pain, infusion site swelling, infusion site warmth, micturition urgency on Aug 22, 2008 from UNITED STATES Additional patient health information: Female patient , 69 years of age, weighting 157.0 lb, was diagnosed with combined immunodeficiency and. Vivaglobin dosage: 69 Ml Daily Sc. During the same period patient was treated with VALIUM (View Valium Review and Valium Label ), MULTIPLE VITAMINS (View Multiple Vitamins Review and Multiple Vitamins Label ), SLEEPING PILL (LITTLE WHITE PILL) (View Sleeping Pill (little White Pill) Review and Sleeping Pill (little White Pill) Label ).

6439188-X | Headache
Adverse event was reported on Dec 12, 2008 by a Female patient taking Vivaglobin (View Usage) (Dosage: Sc) was diagnosed with immunodeficiency and. Location: UNITED STATES , 74 years of age, After Vivaglobin was administered, patient had the following side effects: headache (What is headache?). During the same period patient was treated with VITAMINS (View Vitamins Review and Vitamins Label ). Patient was hospitalized.

6436740-2 | Cerebrovascular Accident, Headache, Hemiparesis, Intracranial Venous Sinus Thrombosis, Urticaria
on Oct 28, 2009 Female patient from UNITED STATES , weighting 130.0 lb, was diagnosed with hypogammaglobulinaemia and was treated with Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: cerebrovascular accident, headache (What is headache?), hemiparesis, intracranial venous sinus thrombosis, urticaria. Vivaglobin dosage: 5.28 Gra,s (33 Ml) Weekly Subcutaneous. During the same period patient was treated with YAZ (Oral) (View Yaz Review and Yaz Label ), SINGULAIR (TOPIRAMATE) (View Singulair (topiramate) Review and Singulair (topiramate) Label ), TOPAMAX (View Topamax Review and Topamax Label ), VITAMIN B12 (View Vitamin B12 Review and Vitamin B12 Label ), ZYRTEC (View Zyrtec Review and Zyrtec Label ), ALEVE (View Aleve Review and Aleve Label ), IMITREX (View Imitrex Review and Imitrex Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ). Patient was hospitalized.

6436731-1 | Superior Vena Caval Occlusion
on Oct 22, 2009 Female patient from UNITED STATES , weighting 115.0 lb, was treated with Vivaglobin (View Usage). Patient had the following side effects: superior vena caval occlusion. Vivaglobin dosage: 50 Ml, 50 Ml Weekly Intravenous (not Otherwise Specified). During the same period patient was treated with ADVAIR HFA (View Advair Hfa Review and Advair Hfa Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ), FLONASE (View Flonase Review and Flonase Label ). Patient was hospitalized.

6421222-4 | Cerebral Haemorrhage, Facial Paresis, Muscular Weakness, Superior Sagittal Sinus Thrombosis, Urticaria
Patient was taking Vivaglobin (View Usage). After Vivaglobin was administered, patient had the following side effects: cerebral haemorrhage, facial paresis, muscular weakness, superior sagittal sinus thrombosis, urticaria on Oct 29, 2009 from UNITED STATES Additional patient health information: Female patient , weighting 123.5 lb, was diagnosed with immunodeficiency common variable, polycystic ovaries and. Vivaglobin dosage: 5.28 G Qweek Sq. During the same period patient was treated with YAZ (1 Tablet Daily Po) (View Yaz Review and Yaz Label ). Patient was hospitalized and became disabled.

6413066-4 | Back Pain, Infusion Related Reaction, Lethargy, Pain In Extremity
Adverse event was reported on Oct 22, 2009 by a Male patient taking Vivaglobin (View Usage) (Dosage: 125ml Q 2 Wks Subcutaneous) was diagnosed with immune system disorder and. Location: UNITED STATES , weighting 374.8 lb, Patient experienced the following unwanted or unexpected effects: back pain (What is back pain?), infusion related reaction, lethargy, pain in extremity.

6406526-3 | Anti-thyroid Antibody Positive, Oedema Peripheral, Polyarthritis, Urticaria
on Sep 30, 2009 Female patient from UNITED STATES , weighting 154.3 lb, was diagnosed with immunodeficiency common variable and was treated with Vivaglobin (View Usage). Patient had the following side effects: anti-thyroid antibody positive, oedema peripheral, polyarthritis, urticaria. Vivaglobin dosage: (14.4 Grams Per Week (88 Ml) Subcutaneous).

6397508-9 | Anti-thyroid Antibody Positive, Oedema Peripheral, Polyarthritis, Thyroxin Binding Globulin Increased, Urticaria
on Sep 18, 2009 Female patient from UNITED STATES , weighting 154.3 lb, was diagnosed with immunodeficiency common variable and was treated with Vivaglobin (View Usage). After Vivaglobin was administered, patient had the following side effects: anti-thyroid antibody positive, oedema peripheral, polyarthritis, thyroxin binding globulin increased, urticaria. Vivaglobin dosage: 14.4 Grams Per Week (88 Ml) (subcutaneous).

6397202-4 | Cerebrovascular Accident, Intracranial Venous Sinus Thrombosis, Urticaria
Patient was taking Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: cerebrovascular accident, intracranial venous sinus thrombosis, urticaria on Sep 24, 2009 from UNITED STATES Additional patient health information: Female patient , weighting 130.0 lb, was diagnosed with hypogammaglobulinaemia and. Vivaglobin dosage: 5.28 Grams (33) Weekly Subcutaneous). During the same period patient was treated with ORAL CONTRACEPTIVE (ORAL CONTRACEPTIVE NOS) (Oral) (View Oral Contraceptive (oral Contraceptive Nos) Review and Oral Contraceptive (oral Contraceptive Nos) Label ), SINGULAIR (View Singulair Review and Singulair Label ), TOPAMAX (View Topamax Review and Topamax Label ), VITAMIN B12 (View Vitamin B12 Review and Vitamin B12 Label ), ZYRTEC (View Zyrtec Review and Zyrtec Label ), ALEVE (View Aleve Review and Aleve Label ), IMITREX (View Imitrex Review and Imitrex Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ). Patient was hospitalized.

6379831-7 | Herpes Simplex
Adverse event was reported on Sep 15, 2009 by a Female patient taking Vivaglobin (View Usage) (Dosage: (8.32 Grams Weekly Subcutaneous)) was diagnosed with immunodeficiency common variable and. Location: UNITED STATES , weighting 160.0 lb, Patient had the following side effects: herpes simplex (What is herpes simplex?).

6337017-6 | Anti-hbc Igg Antibody Positive, Hepatitis B Antigen Positive, Hepatitis B Positive, Transmission Of An Infectious Agent Via A Medicinal Product
on Aug 11, 2009 Male patient from UNITED STATES , child 10 years of age, was treated with Vivaglobin (View Usage). After Vivaglobin was administered, patient had the following side effects: anti-hbc igg antibody positive, hepatitis b antigen positive, hepatitis b positive, transmission of an infectious agent via a medicinal product. Vivaglobin dosage: 7.36 G, Every 7 Days Subcutaneous.

6310853-8 | Meningitis Aseptic, Refusal Of Treatment By Patient, Thrombosis
on Aug 04, 2009 Female patient from UNITED STATES , weighting 300.0 lb, was diagnosed with immunodeficiency common variable and was treated with Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: meningitis aseptic, refusal of treatment by patient, thrombosis. Vivaglobin dosage: (43 Ml 1x/week Subcutaneous).

6283245-8 | Dyspnoea, Erythema, Pruritus, Rash Macular
Patient was taking Vivaglobin (View Usage). Patient had the following side effects: dyspnoea, erythema, pruritus, rash macular on Jul 22, 2009 from UNITED STATES Additional patient health information: Female patient , 37 years of age, weighting 285.0 lb, . Vivaglobin dosage: 18.8 Grams Bid.

6270801-6 | Benign Intracranial Hypertension, Csf Pressure Increased, Diplopia, Headache, Hookworm Infection, Unevaluable Event, Wheezing
Adverse event was reported on Jul 02, 2009 by a Female patient taking Vivaglobin (View Usage) (Dosage: (50 Ml, 50 Ml Weekly Subcutaneous)) was diagnosed with hypogammaglobulinaemia and. Location: UNITED STATES , 46 years of age, After Vivaglobin was administered, patient had the following side effects: benign intracranial hypertension, csf pressure increased, diplopia, headache (What is headache?), hookworm infection, unevaluable event, wheezing.

6262860-1 | Benign Intracranial Hypertension, Csf Pressure Increased, Diplopia, Headache, Hookworm Infection, Unevaluable Event, Vision Blurred, Wheezing
on Jun 25, 2009 Female patient from UNITED STATES , 46 years of age, was diagnosed with hypogammaglobulinaemia and was treated with Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: benign intracranial hypertension, csf pressure increased, diplopia, headache (What is headache?), hookworm infection, unevaluable event, vision blurred, wheezing. Vivaglobin dosage: (50 Ml, 50 Ml Weekly Subcutaneous).

6259406-0 | Injection Site Reaction, Meningitis Aseptic
on Jun 12, 2009 Female patient from UNITED STATES , weighting 263.9 lb, was diagnosed with immunodeficiency common variable and was treated with Vivaglobin (View Usage). Patient had the following side effects: injection site reaction, meningitis aseptic. Vivaglobin dosage: See Image. During the same period patient was treated with OXYGEN (OXYGEN) (View Oxygen (oxygen) Review and Oxygen (oxygen) Label ), LIDOCAINE/PRILOCAINE (LIDOCAINE) (View Lidocaine/prilocaine (lidocaine) Review and Lidocaine/prilocaine (lidocaine) Label ). Patient was hospitalized.

6237669-5 | Influenza Like Illness, Injection Site Reaction, Meningitis Aseptic, Nausea, Neck Pain
Patient was taking Vivaglobin (View Usage). After Vivaglobin was administered, patient had the following side effects: influenza like illness, injection site reaction, meningitis aseptic, nausea (What is nausea?), neck pain on Jun 04, 2009 from UNITED STATES Additional patient health information: Female patient , weighting 263.9 lb, was diagnosed with immunodeficiency and. Vivaglobin dosage: See Image. Patient was hospitalized.

6234773-2 | Deep Vein Thrombosis
Adverse event was reported on May 26, 2009 by a Male patient taking Vivaglobin (View Usage) (Dosage: 9.6 G, 9.6 G Weekly Subcutaneous) was diagnosed with hypogammaglobulinaemia and. Location: UNITED STATES , weighting 199.0 lb, Patient experienced the following unwanted or unexpected effects: deep vein thrombosis (What is deep vein thrombosis?). During the same period patient was treated with NASONEX (View Nasonex Review and Nasonex Label ), ZEGERID (PRILOSEC) (OMEPRAZOLE) (View Zegerid (prilosec) (omeprazole) Review and Zegerid (prilosec) (omeprazole) Label ), AMBIEN (View Ambien Review and Ambien Label ), LIPITOR (View Lipitor Review and Lipitor Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), MTV (DAILY MULTIVITAMIN) (View Mtv (daily Multivitamin) Review and Mtv (daily Multivitamin) Label ).

6220314-2 | Influenza Like Illness, Injection Site Reaction, Meningitis Aseptic
on May 19, 2009 Female patient from UNITED STATES , weighting 263.9 lb, was diagnosed with immunodeficiency common variable and was treated with Vivaglobin (View Usage). Patient had the following side effects: influenza like illness, injection site reaction, meningitis aseptic. Vivaglobin dosage: See Image; Subcutaneous. During the same period patient was treated with BYETTA (View Byetta Review and Byetta Label ), OXYGEN (OXYGEN) (View Oxygen (oxygen) Review and Oxygen (oxygen) Label ), LIDOCAINE/PRILOCAINE (LIDOCAINE) (View Lidocaine/prilocaine (lidocaine) Review and Lidocaine/prilocaine (lidocaine) Label ). Patient was hospitalized.

6220283-5 | Headache, Meningitis Aseptic, Musculoskeletal Stiffness, Neck Pain, Refusal Of Treatment By Patient, Thrombosis
on May 15, 2009 Female patient from UNITED STATES , weighting 300.0 lb, was diagnosed with immunodeficiency common variable and was treated with Vivaglobin (View Usage). After Vivaglobin was administered, patient had the following side effects: headache (What is headache?), meningitis aseptic, musculoskeletal stiffness, neck pain, refusal of treatment by patient, thrombosis. Vivaglobin dosage: 43 Ml 1x/week Subcutaneous, 43 Ml 2x/week Subcutaneous.

6201593-4 | Influenza Like Illness, Meningitis Aseptic, Neck Pain, Vomiting
Patient was taking Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: influenza like illness, meningitis aseptic, neck pain, vomiting on May 13, 2009 from UNITED STATES Additional patient health information: Female patient , weighting 263.9 lb, was diagnosed with immunodeficiency common variable and. Vivaglobin dosage: See Image. During the same period patient was treated with (NEUROPATHY PERIPHERAL), ASTHMA (ASTHMA), PULMONARY HYPERTENSION (PULM (View (neuropathy Peripheral), Asthma (asthma), Pulmonary Hypertension (pulm Review and (neuropathy Peripheral), Asthma (asthma), Pulmonary Hypertension (pulm Label ), OXYGEN (OXYGEN) (View Oxygen (oxygen) Review and Oxygen (oxygen) Label ), LIDOCAINE/PRILOSCAINE (LIDOCAINE) (View Lidocaine/priloscaine (lidocaine) Review and Lidocaine/priloscaine (lidocaine) Label ). Patient was hospitalized.

6197687-2 | Diarrhoea, Dysuria, Pancreatitis, Renal Failure, Renal Failure Acute, Retching, Swelling, Viral Infection, Vomiting
Adverse event was reported on May 11, 2009 by a Male patient taking Vivaglobin (View Usage) (Dosage: (20 Ml Weekly Subcutaneous) ; (subcutaneous) was diagnosed with immunodeficiency and. Location: UNITED STATES , weighting 36.00 lb, Patient had the following side effects: diarrhoea, dysuria, pancreatitis, renal failure, renal failure acute, retching, swelling, viral infection (What is viral infection?), vomiting. Patient was hospitalized.

6196899-1 | Pain
on May 18, 2009 Male patient from UNITED STATES , weighting 205.0 lb, was diagnosed with chronic inflammatory demyelinating polyradiculoneuropathy, immunodeficiency common variable and was treated with Vivaglobin (View Usage). After Vivaglobin was administered, patient had the following side effects: pain (What is pain?). Vivaglobin dosage: 4.8 Gms/30 Ml Weekly Sq.

6193780-9 | Loss Of Consciousness, Myocardial Infarction
on May 06, 2009 Male patient from UNITED STATES , weighting 91.05 lb, was diagnosed with immunodeficiency common variable and was treated with Vivaglobin (View Usage). Patient experienced the following unwanted or unexpected effects: loss of consciousness, myocardial infarction. Vivaglobin dosage: See Image. During the same period patient was treated with DIPHENHYDRAMINE HCL (View Diphenhydramine Hcl Review and Diphenhydramine Hcl Label ), LIDOCAINE/PRILOCAINE (EMLA /00675501/) (View Lidocaine/prilocaine (emla /00675501/) Review and Lidocaine/prilocaine (emla /00675501/) Label ), EPIPEN (View Epipen Review and Epipen Label ), ISONIAZID (View Isoniazid Review and Isoniazid Label ), VALTREX (View Valtrex Review and Valtrex Label ), MULTIVITAMIN (DAILY MULTIVITAMIN) (View Multivitamin (daily Multivitamin) Review and Multivitamin (daily Multivitamin) Label ).

6180675-X | Loss Of Consciousness, Myocardial Infarction
Patient was taking Vivaglobin (View Usage). Patient had the following side effects: loss of consciousness, myocardial infarction on Apr 08, 2009 from UNITED STATES Additional patient health information: Male patient , weighting 91.05 lb, was diagnosed with immunodeficiency common variable and. Vivaglobin dosage: See Image. During the same period patient was treated with DIPHENHYDRAMINE HCL (View Diphenhydramine Hcl Review and Diphenhydramine Hcl Label ), LIDOCAINE/PRILOCAINE (EMLA /00675501/) (View Lidocaine/prilocaine (emla /00675501/) Review and Lidocaine/prilocaine (emla /00675501/) Label ), EPIPEN (View Epipen Review and Epipen Label ), ISONIAZID (View Isoniazid Review and Isoniazid Label ), VALTREX (View Valtrex Review and Valtrex Label ), MULTIVITAMIN (DAILY MULTIVITAMIN) (View Multivitamin (daily Multivitamin) Review and Multivitamin (daily Multivitamin) Label ).